STINGVAX-treated mice exhibited increased tumor-infiltrating lymphocytes (TILs) and an upregulated PD-L1 expression, indicating that STINGVAX is suitable for co-administration with anti-PD-1 therapy (109). The gene discussed is CD274; the disease is neoplasm.